Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL101 for ocular side effects of glaucoma medications
NCT02656394Phase 2Completed
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ocular surface disease (OSD) comparing GL101 with Placebo (2 arms). Primary endpoint: Glaucoma medication ocular side effect symptoms at 4 weeks. Started Jan 2016; status: completed.
02
Drugs
progesterone
03
Conditions
ocular surface disease (OSD)
Beyond the preview
Go deeper on NCT02656394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656394.